Loading...
NPI 1962586073 · Thorndale, PA · Ophthalmology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Guri Bronner is a ophthalmology physician provider located in Thorndale, Pennsylvania. This profile covers 16 Medicare and 2 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Guri Bronner |
| Address | 3000 C G Zinn Rd |
| City | Thorndale |
| State | PA |
| ZIP | 19372 |
| Taxonomy | Ophthalmology Physician |
| NPI Enumerated | October 25, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $3.8M |
| Medicaid | $2.4K |
This provider’s Medicare business is heavily concentrated in intravitreal anti-VEGF therapy: J0178 (Injection, aflibercept) alone generated $2.9M in Medicare revenue (75.1% of the provider’s Medicare revenue) from 4.1K claims with an average paid/claim of $694. The precomputed top 3 Medicare codes account for 87.5% of total Medicare revenue, indicating that a small set of injection and retina-focused services drive most of the Medicare income.
Clinical service mix and operating model are retina-centric: high-volume procedural codes for intravitreal injections (J0178, 67028) and retinal imaging (92134) dominate the Medicare ledger, while routine ophthalmic office visit codes (92014, 92012) appear as the principal evaluation-and-management complements. The presence of J3590 (Unclassified biologics) and J2778 (ranibizumab) further supports a practice built around biologic injections and retina disease management rather than broad surgical ophthalmology.
Competitive standing on Medicare is strong for multiple retina-related codes: J0178 ranks #63 of 3204 providers nationally (98th percentile) and 92014 ranks #74 of 35415 providers nationally (100th percentile, labeled an "extreme outlier"), while 92134 ranks in the 99th percentile. These ranks indicate the provider operates at substantially higher volumes than most peers for both injection administration and retinal imaging services, consistent with a high-throughput retina/injection clinic.
Not all high-revenue codes are outliers: J3590 (Unclassified biologics) produced $215.8K (5.7% of Medicare revenue) and is characterized as "typical, unremarkable" volume (55th percentile), suggesting that some non-standard biologic billing lines are present but not at exceptional volumes compared with specialized peers. This mixed profile suggests primary reliance on a few dominant codes with secondary, routine use of other biologic and imaging codes.
Payer mix is effectively Medicare-dominant: lifetime Medicare revenue is $3.8M versus lifetime Medicaid revenue of $2.4K, so Medicaid constitutes a vanishing share of reported public-payer revenue. For operational and contracting considerations, this provider should be treated as functionally single-payer (Medicare-focused) in scale and strategic importance.
Medicaid billing is narrowly concentrated and low in scale: the precomputed top 3 Medicaid codes account for 100.0% of Medicaid revenue, with 92134 and 92014 comprising the observable Medicaid activity ($1.6K and $912 respectively). Both Medicaid codes sit in low-to-mid state percentiles (92134 at the 29th percentile and 92014 at the 27th percentile), indicating routine in-state volumes and no dominant Medicaid market position.
There is a measurable concentration risk in the revenue mix due to dependence on a few high-volume codes: with 75.1% of Medicare revenue coming from J0178 and the top 3 Medicare codes totaling 87.5% of Medicare revenue, changes in utilization patterns, reimbursement, or access to aflibercept could materially affect revenue. Analysts should flag the sensitivity of this profile to policy or clinical shifts affecting anti-VEGF utilization.
Provider tenure is long-standing: the NPI was enumerated on 2006-10-25 (≈20 years ago), indicating an established billing history and likely sustained relationships with Medicare over two decades, which supports interpreting current high-volume patterns as persistent operational specialization rather than a transient reporting artifact.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
16 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 4,130 | $690 | $2.9M |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 2,870 | $90 | $255.5K |
| J3590 | Unclassified biologics | 100 | $2,120 | $215.8K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 2,220 | $90 | $195.5K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 3,670 | $30 | $113.8K |
| J2778 | Injection, ranibizumab, 0.1 mg | 510 | $180 | $94.1K |
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 730 | $60 | $45.9K |
| 67228 | In retinopathy, tiny new vessels grow profusely and fibrous tissue proliferates in between the layers of the retina, which may extend into the optic nerve and vitreous, clear gel that fills the space… | 20 | $270 | $6.4K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 50 | $100 | $4.3K |
| 92250 | Code 92250 describes the taking of fundus photographs, that is, photographs of the posterior segment of the inner aspect of the eye, to document alterations in the optic nerve head, retinal vessels,… | 140 | $30 | $3.9K |
Showing 1–10 of 16
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 16 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
16 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 7 | 140 | 830 | $690 | $865.1K |
| J2778 | 47 | 70 | 1,030 | $190 | $417.1K |
| 67028 | 23 | 180 | 600 | $90 | $87.5K |
| J3590 | 2 | 10 | 40 | $1,690 | $78K |
| 92014 | 1 | 1,570 | 130 | $80 | $21K |
| 99214 | 18,238 | 23,230 | 100 | $80 | $14.5K |
| 92012 | 51 | 930 | 80 | $60 | $14K |
| 92134 | 23 | 1,320 | 60 | $30 | $8.4K |
| 99213 | 19,091 | 22,370 | 70 | $60 | $7.7K |
| 67228 | 10 | 20 | 20 | $230 | $5.4K |
Showing 1–10 of 16
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
2 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 100 | $20 | $1.6K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 60 | $20 | $910 |
How this provider's Medicaid billing volume and revenue compare to other Pennsylvania providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Pennsylvania median
2 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 625 | 860 | 240 | $40 | $37K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 130 | 180 | 290 | $20 | $24.8K |
Other providers in the same ZIP code as Guri Bronner, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| William Brown | PA | Family Medicine Physician | $589.6K | $0 |
| Christopher Schreier | PA | Family Medicine Physician | $280.3K | $0 |
| Michael Sabadish | PA | Clinical Cardiac Electrophysiology Physician | $265.5K | $0 |
| Michael Carnuccio | PA | Family Medicine Physician | $252.3K | $0 |
| Nadeem Paroya | PA | Family Medicine Physician | $175.3K | $5.2K |
| Rajesh Reddy | PA | Cardiovascular Disease Physician | $132K | $5.6K |
| Alexander Shpilman | PA | Cardiovascular Disease Physician | $130.1K | $610 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.